However, the range of clinically applicable gene transfer techniques available today mean that the additional knockout of a molecule like SHP-1 from T-cells already undergoing genetic modification becomes a much more straightforward proposition, making it more likely that the beneficial anti-cancer properties of SHP-1−/− T-cells can be exploited in the clinic in the near future. This evidence concerns the gene PTPN6 and cancer.